leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   93 Trials   93 Trials   2194 News 


«12...2223242526272829303132...3334»
  • ||||||||||  Enrollment closed, Trial primary completion date:  Regulation of Cervical Mucus Secretion (clinicaltrials.gov) -  Oct 27, 2017   
    P4,  N=10, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
    Trial suspension, Trial primary completion date, PD(L)-1 Biomarker:  Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) -  Oct 16, 2017   
    P2,  N=42, Suspended, 
    N=30 --> 36 Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Apr 2020
  • ||||||||||  goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
    Enrollment closed, Surgery:  RADICALS-HD: RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery (clinicaltrials.gov) -  Oct 13, 2017   
    P3,  N=4236, Active, not recruiting, 
    Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Apr 2020 Recruiting --> Active, not recruiting
  • ||||||||||  Erleada (apalutamide) / J&J
    Enrollment open:  A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) -  Aug 3, 2017   
    P2,  N=33, Recruiting, 
    Initiation date: Jul 2017 --> Dec 2017 | Trial primary completion date: Jul 2021 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Enrollment closed:  Females, Aging, Metabolism, and Exercise (clinicaltrials.gov) -  Jul 18, 2017   
    P=N/A,  N=132, Active, not recruiting, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) -  Jul 17, 2017   
    P2,  N=19, Terminated, 
    Recruiting --> Active, not recruiting N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Biomarker, Enrollment open:  Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) -  Jul 16, 2017   
    P4,  N=58, Recruiting, 
    N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Not yet recruiting --> Recruiting
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Enrollment open:  Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) -  Jul 14, 2017   
    P=N/A,  N=72, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
    Enrollment open, PD(L)-1 Biomarker:  Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) -  Jun 8, 2017   
    P2,  N=42, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Orgalutran (ganirelix acetate) / Organon
    Phase classification:  Follicle-Stimulating Hormone (FSH) and the Onset of Puberty (clinicaltrials.gov) -  May 22, 2017   
    P,  N=11, Completed, 
    Active, not recruiting --> Completed Phase classification: P=N/A --> P
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
    Enrollment change, PD(L)-1 Biomarker:  Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) -  Apr 25, 2017   
    P2,  N=42, Not yet recruiting, 
    Recruiting --> Active, not recruiting N=60 --> 42
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Trial completion, Enrollment change, Trial primary completion date:  Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) -  Apr 12, 2017   
    P2,  N=30, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Dec 2018 Active, not recruiting --> Completed | N=48 --> 30 | Trial primary completion date: Jun 2018 --> Apr 2017